Study of NGX-1998 for the Treatment of Postherpetic Neuralgia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01228838 |
Recruitment Status :
Completed
First Posted : October 27, 2010
Last Update Posted : September 10, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postherpetic Neuralgia Pain | Drug: NGX-1998 Drug: Placebo Liquid | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 183 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter Randomized, Double-Blind, Controlled Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Two Capsaicin Concentration Variations of NGX-1998 (10% or 20% w/w) in Subjects With Postherpetic Neuralgia (PHN) |
Study Start Date : | October 2010 |
Actual Primary Completion Date : | September 2011 |
Actual Study Completion Date : | September 2011 |
Arm | Intervention/treatment |
---|---|
Experimental: NGX-1998, 10% w/w capsaicin |
Drug: NGX-1998
Capsaicin topical liquid to be applied for 5 minutes one time only. |
Experimental: NGX-1998, 20% w/w capsaicin |
Drug: NGX-1998
Capsaicin topical liquid to be applied for 5 minutes one time only. |
Placebo Comparator: Placebo liquid |
Drug: Placebo Liquid
Placebo topical liquid to be applied for 5 minutes one time only. |
- Percent change from baseline in the "average pain for the past 24 hours" NPRS score during Weeks 2-8. [ Time Frame: Weeks 2-8 ]
- Absolute change and percent change from baseline in the "average pain for the past 24 hours" NPRS score at Week 8 and 12 [ Time Frame: Week 8 and Week 12 ]
- Absolute change and percent change from baseline in the "average pain for the past 24 hours" NPRS score during Weeks 2-12. [ Time Frame: Weeks 2-12 ]
- Proportion of subjects with at least a 30% decrease from baseline in their "average pain for the past 24 hours" NPRS during Weeks 2-8, Weeks 2-12, at Week 8 and Week 12. [ Time Frame: Weeks 2-12 ]
- Proportion of subjects with at least a 2 unit decrease from baseline in their "average pain for the past 24 hours" NPRS during Weeks 2-8, Weeks 2-12, at Week 8 and Week 12. [ Time Frame: Week 8 and Week 12 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Between 18 and 90 years of age, inclusive.
- Diagnosis of PHN with at least six (6) months of pain since shingles vesicle crusting.
- Average NPRS scores for PHN-associated pain during Days -14 to -4 of 4 to 9, inclusive.
- Intact, unbroken skin over the painful area(s) to be treated.
- If taking chronic pain medications, be on a stable (not PRN) regimen for at least 21 days prior to Test Article Application Visit and willing to maintain medications at same stable dose(s) and schedule throughout the study.
- Female subjects with child-bearing potential must have a negative serum beta human chorionic gonadotropin (hCG) pregnancy test, to be performed within 7 days of the Test Article Application Visit.
- All subjects must be willing to use effective methods of birth control and/or refrain from participating in a conception process during the study.
- If breastfeeding, the subject should agree not to breastfeed their child after treatment on the treatment day.
- Be willing and able to comply with protocol requirements for the duration of study participation.
- Subjects must sign an informed consent form for this study approved by the Investigator's Institutional Review Board/Independent Ethics Committee (IRB/IEC).
Exclusion Criteria:
- Concomitant opioid medication, unless orally or transdermally administered and not exceeding a total daily dose of morphine 60 mg/day, or equivalent. Parenteral opioid use is excluded.
- Unavailability of an effective medication for treatment related discomfort for the subject, such as unwillingness to use opioid analgesics during study treatment, or high tolerance to opioids precluding the ability to relieve treatment-associated discomfort.
- Active substance abuse or history of chronic substance abuse within the past year, or prior chronic substance abuse judged likely to recur during the study period.
- Recent use (within 21 days preceding the Test Article Application Visit [Day 0]) of any topically applied pain medication on the painful areas.
- Receipt of Qutenza® within 12 months of the Test Article Application Visit (Day 0). Subjects who have received Qutenza® 12 months or more before Test Article Application Visit (Day 0), and who did not respond should also be excluded.
- Participation in another drug research study within 30 days preceding the Test Article Application Visit (Day 0).
- Current use of any Class I anti-arrhythmic drugs or III anti-arrhythmic drugs.
- Diabetes mellitus, unless well-controlled as evidenced by an HBA1c level less than or equal to nine percent (9%).
- A recent history of cardiovascular or cerebrovascular events or unstable hypertension, unless adequately controlled by medication.
- Significant pain of an etiology other than PHN, for example, compression-related neuropathies, fibromyalgia or arthritis.
- Painful PHN areas located on the face, above the hairline of the scalp, and/or in proximity to mucous membranes.
- Any implanted medical device for the treatment of neuropathic pain.
- History of hypersensitivity to capsaicin, local anesthetics or any components of the CTLs, Cleansing Gel or the lidocaine (2.5%) / prilocaine (2.5%) topical anesthetic cream.
- Patients with glucose-6 phosphate dehydrogenase deficiencies.
- Significant ongoing or untreated abnormalities or conditions, including active malignancy defined as treatment required in the last five (5) years, that in the opinion of the Investigator would interfere with the ability to complete the study or the evaluation of AEs.
- Patients with congenital or idiopathic methemoglobinemia.
- Recent history of a significant medical-surgical intervention in the judgment of the Investigator; examples include but are not limited to major surgery or percutaneous angioplasty/coronary artery stent placement within the past 3 months, and receipt of immunosuppressive therapy within 3 months, prior to the Test Article Application Visit [Day 0].
- Evidence of cognitive impairment including dementia that may interfere with subject's ability to complete daily pain diaries requiring subject's recall of average PHN pain level in the past 24 hours.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01228838
United States, Alabama | |
NeurogesX Investigational Site | |
Huntsville, Alabama, United States | |
United States, Arizona | |
NeurogesX Investigational Site | |
Tucson, Arizona, United States | |
United States, California | |
NeurogesX Investigational Site | |
Irvine, California, United States | |
NeurogesX Investigational Site | |
La Jolla, California, United States | |
NeurogesX Investigational Site | |
Napa, California, United States | |
NeurogesX Investigational Site | |
San Francisco, California, United States | |
NeurogesX Investigational Site | |
Santa Monica, California, United States | |
United States, Florida | |
NeurogesX Investigational Site | |
New Port Richey, Florida, United States | |
NeurogesX Investigational Site | |
North Palm Beach, Florida, United States | |
NeurogesX Investigational Site | |
Sarasota, Florida, United States | |
NeurogesX Investigational Site | |
St. Petersburg, Florida, United States | |
United States, Georgia | |
NeurogesX Investigational Site | |
Marietta, Georgia, United States | |
United States, Idaho | |
NeurogesX Investigational Site | |
Boise, Idaho, United States | |
United States, Illinois | |
NeurogesX Investigational Site | |
Bloomington, Illinois, United States | |
United States, Iowa | |
NeurogesX Investigational Site | |
West Des Moines, Iowa, United States | |
United States, Kansas | |
NeurogesX Investigational Site | |
Kansas City, Kansas, United States | |
United States, Kentucky | |
NeurogesX Investigational Site | |
Lexington, Kentucky, United States | |
United States, Louisiana | |
NeurogesX Investigational Site | |
Shreveport, Louisiana, United States | |
United States, Massachusetts | |
NeurogesX Investigational Site | |
Hyannis, Massachusetts, United States | |
United States, Michigan | |
NeurogesX Investigational Site | |
Ann Arbor, Michigan, United States | |
United States, Minnesota | |
NeurogesX Investigational Site | |
Minneapolis, Minnesota, United States | |
United States, Mississippi | |
NeurogesX Investigational Site | |
Hattiesburg, Mississippi, United States | |
United States, New York | |
NeurogesX Investigational Site | |
Albany, New York, United States | |
NeurogesX Investigational Site | |
Rochester, New York, United States | |
United States, North Carolina | |
NeurogesX Investigational Site | |
Hickory, North Carolina, United States | |
NeurogesX Investigational Site | |
Winston-Salem, North Carolina, United States | |
United States, Oregon | |
NeurogesX Investigational Site | |
Portland, Oregon, United States | |
United States, Pennsylvania | |
NeurogesX Investigational Site | |
Altoona, Pennsylvania, United States | |
United States, Texas | |
NeurogesX Investigational Site | |
San Antonio, Texas, United States | |
NeurogesX Investigational Site | |
Webster, Texas, United States | |
United States, Utah | |
NeurogesX Investigational Site | |
Salt Lake City, Utah, United States | |
United States, Virginia | |
NeurogesX Investigational Site | |
Richmond, Virginia, United States | |
United States, Washington | |
NeurogesX Investigational Site | |
Seattle, Washington, United States | |
NeurogesX Investigational Site | |
Wenatchee, Washington, United States | |
United States, Wisconsin | |
NeurogesX Investigational Site | |
Madison, Wisconsin, United States |
Study Director: | Trudy Vanhove, MD, PhD, MBA | NeurogesX |
Responsible Party: | NeurogesX |
ClinicalTrials.gov Identifier: | NCT01228838 |
Other Study ID Numbers: |
C204 |
First Posted: | October 27, 2010 Key Record Dates |
Last Update Posted: | September 10, 2012 |
Last Verified: | May 2011 |
postherpetic neuralgia PHN capsaicin herpes zoster |
shingles analgesics neuropathy |
Neuralgia Neuralgia, Postherpetic Peripheral Nervous System Diseases Neuromuscular Diseases |
Nervous System Diseases Pain Neurologic Manifestations |